Philadelphia chromosome-positive human the BCR / ABL tyrosine kinase oncogene of BCR first exon sequences specifically activate

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a nucleotide exchange-promoting activity for p21ras.

  1990cited by this paper
• Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases

  1990cited by this paper
• Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

  1990cited by this paper
• Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

  1990cited by this paper
• Activation of the proto-oncogene p60c-src by point mutations in the SH2 domain

  1990cited by this paper
• A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.

  1990cited by this paper
• bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

  1990cited by this paper
• Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

  1990cited by this paper
• Mechanism of activation of the human trk oncogene.

  1989cited by this paper
• Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential.

  1989cited by this paper
• The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc

  1989cited by this paper
• Nucleotide sequence analysis of human abl and bcr-abl cDNAs.

  1989cited by this paper
• Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells

  1989cited by this paper
• N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl.

  1989cited by this paper
• Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia.

  1989cited by this paper
• Molecular pathogenesis of Ph-positive leukemias.

  1989cited by this paper
• The viral and cellular forms of the Abelson (abl) oncogene.

  1988cited by this paper
• A novel viral oncogene with structural similarity to phospholipase C

  1988cited by this paper
• Sequence similarity of phospholipase C with the non-catalytic region of src

  1988cited by this paper
• Molecular cloning of a 5' segment of the genomic phl gene defines a new breakpoint cluster region (bcr2) in Philadelphia-positive acute leukemias.

  1988cited by this paper
• The protein kinase family: conserved features and deduced phylogeny of the catalytic domains.

  1988cited by this paper
• bcr genes and transcripts.

  1988cited by this paper
• Phosphorylation of cellular proteins in Rous sarcoma virus-infected cells: analysis by use of anti-phosphotyrosine antibodies

  1988cited by this paper
• Activation of pp60c-src transforming potential by mutations altering the structure of an amino terminal domain containing residues 90-95.

  1988cited by this paper
• Construction and Characterization of a Retroviral Vector Demonstrating Efficient Expression of Cloned cDNA Sequences

  1988cited by this paper
• Non-catalytic domains of cytoplasmic protein-tyrosine kinases: regulatory elements in signal transduction.

  1988cited by this paper
• In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

  1987cited by this paper
• The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.

  1987cited by this paper
• Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert

  1987cited by this paper
• A tail of two src's: mutatis mutandis.

  1987cited by this paper
• Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein

  1986cited by this paper
• Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.

  1986cited by this paper
• Alternative 5' exons in c-abl mRNA.

  1986cited by this paper
• Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules

  1986cited by this paper
• Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.

  1986cited by this paper
• A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps

  1986cited by this paper
• Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene.

  1986cited by this paper
• A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

  1986cited by this paper
• Requirement for c-ras proteins during viral oncogene transformation

  1986cited by this paper
• Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

  1985cited by this paper
• Transfer of genes into embryonal carcinoma cells by retrovirus infection: efficient expression from an internal promoter.

  1985cited by this paper
• Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products

  1985cited by this paper
• Transfected DNA is mutated in monkey, mouse, and human cells

  1984cited by this paper
• Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

  1984cited by this paper
• Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells.

  1983cited by this paper
• Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation.

  1983cited by this paper
• Site-directed deletions of Abelson murine leukemia virus define 3' sequences essential for transformation and lethality

  1983cited by this paper
• Long-term culture of B lymphocytes and their precursors from murine bone marrow.

  1982cited by this paper
• The transforming proteins of Rous sarcoma virus, Harvey sarcoma virus and Abelson virus contain tightly bound lipid.

  1982cited by this paper
• Lethal effect of the Abelson murine leukemia virus transforming gene product.

  1981cited by this paper
• High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections.

  1978cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• No citing papers are available for this paper.